Lantheus Reports Strong Q1 GAAP EPS, Advances Key Products Despite PDUFA Delay
LNTH sits 90% above its 52-week low of $47.25.
Summary
Lantheus Holdings reported its first quarter 2026 financial results, with GAAP fully diluted earnings per share significantly increasing by 76.5% to $1.80, and worldwide revenue growing 1.2% to $377.3 million. However, adjusted fully diluted EPS saw a 4.6% decrease to $1.46. The company also announced FDA approval for PYLARIFY TruVu, a new formulation of its market-leading PSMA PET imaging agent, and tentative FDA approval for PNT2003, a potential radioequivalent for GEP-NETs. Conversely, the FDA extended the PDUFA date for LNTH-2501 by three months to June 29, 2026, to review manufacturing-related information. Full-year 2026 financial guidance for revenue and adjusted EPS was reiterated. This mixed report, with strong GAAP performance alongside a dip in adjusted earnings and a blend of positive product approvals and a regulatory delay, provides a complex picture for investors. Traders will closely watch the commercial rollout of PYLARIFY TruVu, the path to full approval for PNT2003, and the final FDA decision on LNTH-2501 in June.
At the time of this announcement, LNTH was trading at $89.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6B. The 52-week trading range was $47.25 to $108.91. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.